Exploring Next-Generation High DAR TOPO1i x DDRi Dual Payload ADCs to Improve Efficacy, Overcome Resistance & Enhance Safety

• Leveraging Sutro’s cell-free expression and site-specific technologies to develop homogeneous, high-DAR TOPO1i × DDRi dual payload ADCs
• Demonstrating synergistic activity of TOPO1i with proprietary DDR inhibitors, including PARPi and ATRi to overcome DNA repair and drug efflux mediated resistance
• Demonstrating superior preclinical efficacy of TOPO1i × DDRi dpADCs compared with single payload ADCs

Speakers:

Krishna Bajjuri

Executive Director, ADC Chemistry & Discovery

Sutro Biopharma